Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

BACKGROUND: Ion channel inhibition may offer protection against coronavirus disease 2019 (COVID-19). Inflammation and reduced platelet count occur during COVID-19 but precise quantification of risk thresholds is unclear. The Recov ery-SIRIO study aimed to assess clinical effects of amiodarone and ve...

Full description

Bibliographic Details

Published in:	Cardiology Journal
Main Authors:	Eliano P. Navarese, Przemysław Podhajski, Felicita Andreotti, Giuseppe La Torre, Robert Gajda, Adrian Radziwanowski, Małgorzata Nowicka, Paweł Bukowski, Jacek Gajda, Maciej Omyła, Piotr Lackowski, Maciej Piasecki, Małgorzata Jasiewicz, Paweł Szymański, Łukasz Pietrzykowski, Piotr Michalski, Aldona Kubica, Iwona Urbanowicz, Nicola Orsini, Max Conte, Jarosław Pinkas, Marc A. Brouwer, Jacek Kubica
Format:	Article
Language:	English
Published:	Via Medica 2022-09-01
Subjects:	amiodarone verapamil COVID-19 ion-channel inhibition randomized trial
Online Access:	https://journals.viamedica.pl/cardiology_journal/article/view/88627